Botulinum Neurotoxin Light Chains Expressed by Defective Herpes Simplex Virus Type-1 Vectors Cleave SNARE Proteins and Inhibit CGRP Release in Rat Sensory Neurons

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2019 Feb 23

PMID 30791373

Citations 13

Authors

Charles Joussain

Olivier Le Coz

Andrey Pichugin

Peggy Marconi

Filip Lim

Mariaconcetta Sicurella

Andrea Salonia

Francesco Montorsi

Francisco Wandosell

Keith Foster

Francois Giuliano

Alberto L Epstein

Alejandro Aranda Munoz

Affiliations

Soon will be listed here.

Abstract

A set of herpes simplex virus type 1 (HSV-1) amplicon vectors expressing the light chains (LC) of botulinum neurotoxins (BoNT) A, B, C, D, E and F was constructed. Their properties have been assessed in primary cultures of rat embryonic dorsal root ganglia (DRG) neurons, and in organotypic cultures of explanted DRG from adult rats. Following infection of primary cultures of rat embryonic DRG neurons, the different BoNT LC induced efficient cleavage of their corresponding target Soluble N-ethylmaleimide-sensitive-factor Attachment protein Receptor (SNARE) protein (VAMP, SNAP25, syntaxin). A similar effect was observed following infection by BoNT-A LC of organotypic cultures of adult rat DRG. To quantify and compare the functional activities of the different BoNT LC, the inhibition of calcitonin gene-related protein (CGRP) secretion was assessed in DRG neurons following infection by the different vectors. All BoNT-LC were able to inhibit CGRP secretion although to different levels. Vectors expressing BoNT-F LC displayed the highest inhibitory activity, while those expressing BoNT-D and -E LC induced a significantly lower CGRP release inhibition. Cleavage of SNARE proteins and inhibition of CGRP release could be detected in neuron cultures infected at less than one transducing unit (TU) per neuron, showing the extreme efficacy of these vectors. To our knowledge this is the first study investigating the impact of vector-expressed transgenic BoNT LC in sensory neurons.

Citing Articles

Non-replicative herpes simplex virus genomic and amplicon vectors for gene therapy - an update.

Le Hars M, Joussain C, Jegu T, Epstein A Gene Ther. 2024; .

PMID: 39533042 DOI: 10.1038/s41434-024-00500-x.

Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications.

Rasetti-Escargueil C, Palea S Toxins (Basel). 2024; 16(6).

PMID: 38922155 PMC: 11209287. DOI: 10.3390/toxins16060261.

Type I collagen concentration affects neurite outgrowth of adult rat DRG explants by altering mechanical properties of hydrogels.

Nguyen U, Lee F, Caparaso S, Leoni J, Redwine A, Wachs R J Biomater Sci Polym Ed. 2023; 35(2):164-189.

PMID: 37847579 PMC: 11611068. DOI: 10.1080/09205063.2023.2272479.

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review.

Blumenfeld A, Lipton R, Silberstein S, Tepper S, Charleston 4th L, Landy S Neurol Ther. 2023; 12(5):1533-1551.

PMID: 37542624 PMC: 10444724. DOI: 10.1007/s40120-023-00529-x.

OnabotulinumtoxinA effects on trigeminal nociceptors.

Moore A, Nelson M, Wickware C, Choi S, Moon G, Xiong E Cephalalgia. 2023; 43(2):3331024221141683.

PMID: 36751871 PMC: 10652784. DOI: 10.1177/03331024221141683.

References

Cuchet D, Ferrera R, Lomonte P, Epstein A . Characterization of antiproliferative and cytotoxic properties of the HSV-1 immediate-early ICPo protein. J Gene Med. 2005; 7(9):1187-99. DOI: 10.1002/jgm.761. View

Krisky D, Wolfe D, Goins W, Marconi P, Ramakrishnan R, Mata M . Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 1999; 5(12):1593-603. DOI: 10.1038/sj.gt.3300766. View

Ahnert-Hilger G, Weller U . Comparison of the intracellular effects of clostridial neurotoxins on exocytosis from streptolysin O-permeabilized rat pheochromocytoma (PC 12) and bovine adrenal chromaffin cells. Neuroscience. 1993; 53(2):547-52. DOI: 10.1016/0306-4522(93)90219-6. View

Gayral M, Lulka H, Hanoun N, Biollay C, Selves J, Vignolle-Vidoni A . Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors. Hum Gene Ther. 2014; 26(2):104-13. PMC: 4326267. DOI: 10.1089/hum.2014.072. View

Lawrence G, Foran P, Dolly J . Distinct exocytotic responses of intact and permeabilised chromaffin cells after cleavage of the 25-kDa synaptosomal-associated protein (SNAP-25) or synaptobrevin by botulinum toxin A or B. Eur J Biochem. 1996; 236(3):877-86. DOI: 10.1111/j.1432-1033.1996.00877.x. View

Oehmig A, Fraefel C, Breakefield X . Update on herpesvirus amplicon vectors. Mol Ther. 2004; 10(4):630-43. DOI: 10.1016/j.ymthe.2004.06.641. View

Bakheit A, Pittock S, Moore A, Wurker M, Otto S, Erbguth F . A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 2002; 8(6):559-65. DOI: 10.1046/j.1468-1331.2001.00277.x. View

Casadevall A, Dermody T, Imperiale M, Sandri-Goldin R, Shenk T . Dual-Use Research of Concern (DURC) Review at American Society for Microbiology Journals. mBio. 2015; 6(4):e01236. PMC: 4542189. DOI: 10.1128/mBio.01236-15. View

Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W . Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011; 60(4):742-50. DOI: 10.1016/j.eururo.2011.07.002. View

10.

Marconi P, Manservigi R, Epstein A . HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases. Curr Opin Drug Discov Devel. 2010; 13(2):169-83. View

11.

Jankovic J, Comella C, Hanschmann A, Grafe S . Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011; 26(8):1521-8. DOI: 10.1002/mds.23658. View

12.

Schiavo G, Matteoli M, Montecucco C . Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000; 80(2):717-66. DOI: 10.1152/physrev.2000.80.2.717. View

13.

Montecucco C, Schiavo G . Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol. 1994; 13(1):1-8. DOI: 10.1111/j.1365-2958.1994.tb00396.x. View

14.

Pasricha P, Ravich W, HENDRIX T, Sostre S, Jones B, Kalloo A . Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med. 1995; 332(12):774-8. DOI: 10.1056/NEJM199503233321203. View

15.

Jahn R, Scheller R . SNAREs--engines for membrane fusion. Nat Rev Mol Cell Biol. 2006; 7(9):631-43. DOI: 10.1038/nrm2002. View

16.

Pirazzini M, Rossetto O, Eleopra R, Montecucco C . Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017; 69(2):200-235. PMC: 5394922. DOI: 10.1124/pr.116.012658. View

17.

Boyd R, Duggan M, Shone C, Foster K . The effect of botulinum neurotoxins on the release of insulin from the insulinoma cell lines HIT-15 and RINm5F. J Biol Chem. 1995; 270(31):18216-8. DOI: 10.1074/jbc.270.31.18216. View

18.

Donald S, Elliott M, Gray B, Hornby F, Lewandowska A, Marlin S . A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo. Pharmacol Res Perspect. 2018; 6(6):e00446. PMC: 6261930. DOI: 10.1002/prp2.446. View

19.

Nitti V, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C . OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2012; 189(6):2186-93. DOI: 10.1016/j.juro.2012.12.022. View

20.

Ferrera R, Cuchet D, Zaupa C, Revol-Guyot V, Ovize M, Epstein A . Efficient and non-toxic gene transfer to cardiomyocytes using novel generation amplicon vectors derived from HSV-1. J Mol Cell Cardiol. 2004; 38(1):219-23. DOI: 10.1016/j.yjmcc.2004.11.014. View